Brooks Women’s Adrenaline GTS 25 Supportive Running & Walking Shoe – White/Black/White — 19% Off

Women's Style

  • Lightweight
Brooks Women’s Adrenaline GTS 25 Supportive Running & Walking Shoe – White/Black/White — 19% Off

$124.95 $154.95

19% off You save $30.00

In Stock Scarce

Get Deal on Amazon (opens in a new tab)

HotFreshDeals may earn a commission from qualifying purchases. Learn more

Brooks. Now $124.95 (was $154.95). Save 19%. Only 2 left in stock – order soon..

Product Details

  • THIS WOMEN’S SHOE IS FOR: The Adrenaline GTS 25 is perfect for runners and walkers seeking reliable support and a smooth ride. Featuring holistic GuideRails for Go-To Support and soft, dynamic premium nitrogen-infused DNA LOFT v3 cushioning, it delivers distraction-free comfort mile after mile. This Brooks Adrenaline GTS 25 is a certified PDAC A5500 Diabetic shoe and has been granted the APMA Seal of Acceptance. Predecessor: Adrenaline GTS 24.
  • GUIDERAILS HOLISTIC SUPPORT SYSTEM: Our innovative technology - known as “GTS” for “Go-To Support” - supports your body in its natural motion path while keeping excess movement in check.
  • SOFT & DYNAMIC CUSHIONING: Even more premium nitrogen-infused DNA Loft v3 cushioning delivers lightweight softness, and feel-good comfort mile after mile.
  • TRUSTED FIT: The breathable engineered mesh upper and flat-knit collar offer a secure, comfortable fit, providing both structure and flexibility to accommodate natural movement during active use.
  • SMOOTH TRANSITIONS: The specially designed outsole and midsole work together to promote seamless transitions, ensuring comfort and support for every step, so you can stay active longer.

Product Information

  • Brand: Brooks
  • ASIN: B0DM3L4F18
  • Availability: In Stock Scarce
Learn more about this product

Brooks Women’s Adrenaline GTS 25 Supportive Running & Walking Shoe – White/Black/White – 7 Medium is a Women's Style product from Brooks.

A notable feature: Lightweight.

Current availability: In Stock Scarce.

Report Deal

What is wrong with this deal?